Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although multimodality treatment can induce high rate of remission in many subtypes of non-Hodgkin's lymphoma (NHL), significant proportions of patients relapse with incurable disease. The effect of human bone marrow (BM) mesenchymal stem cells (MSC) on tumor cell growth is controversial, and no specific information is available on the effect of BM-MSC on NHL. METHODOLOGY/PRINCIPAL FINDINGS: The effect of BM-MSC was analyzed in two in vivo models of disseminated non-Hodgkin's lymphomas with an indolent (EBV(-) Burkitt-type BJAB, median survival = 46 days) and an aggressive (EBV(+) B lymphoblastoid SKW6.4, median survival = 27 days) behavior in nude-SCID mice. Intra-peritoneal (i.p.) injection of MSC (4 days after i.p. injection of lymphoma cells) significantly increased the overall survival at an optimal MSC:lymphoma ratio of 1:10 in both xenograft models (BJAB+MSC, median survival = 58.5 days; SKW6.4+MSC, median survival = 40 days). Upon MSC injection, i.p. tumor masses developed more slowly and, at the histopathological observation, exhibited a massive stromal infiltration coupled to extensive intra-tumor necrosis. In in vitro experiments, we found that: i) MSC/lymphoma co-cultures modestly affected lymphoma cell survival and were characterized by increased release of pro-angiogenic cytokines with respect to the MSC, or lymphoma, cultures; ii) MSC induce the migration of endothelial cells in transwell assays, but promoted endothelial cell apoptosis in direct MSC/endothelial cell co-cultures. CONCLUSIONS/SIGNIFICANCE: Our data demonstrate that BM-MSC exhibit anti-lymphoma activity in two distinct xenograft SCID mouse models of disseminated NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 1×
“. The deleterious effects could derive from different MSC characteristics. Indeed, MSC specifically migrate toward sites of active tumorigenesis, where they could integrate the specialized tumor niche, contribute to the development of tumor-associated fibroblasts and myofibroblasts”
BackgroundChen, L., Tredget, E. E., Wu, P. Y. G., & Wu, Y. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001886 · Cited by 1,610
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 2×
“In fact, it has been shown that the immunosuppressive effect of MSC might favor tumor growth in allogeneic animals [12].”
BackgroundCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
Ramasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386
Research works printed but not linked: 28
- CA Clarke, 2002, Changing incidence of non-Hodgkin lymphomas in the United States., Cancer, 94, 2015, 10.1002/cncr.10403 · DOI · Paper page
- JO Armitage, 1998, New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes: Non-Hodgkin's Lymphoma classification project., J Clin Oncol, 16, 2780, 10.1200/JCO.1998.16.8.2780 · DOI · Paper page
- R Taub, 1982, Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells., Proc Natl Acad Sci U S A, 79, 7837, 10.1073/pnas.79.24.7837 · DOI · Paper page
- NA Bhowmick, 2004, Stromal fibroblasts in cancer initiation and progression., Nature, 432, 332, 10.1038/nature03096 · DOI · Paper page
- NE Kaya, 2007, Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an “angiogenic switch.”, Leuk Res, 31, 899, 10.1016/j.leukres.2006.11.024 · doi:10.1016/j.leukres.2006.11.024
- J Edelmann, 2008, Bone marrow fibroblasts induce expression of PI3K/NF-kB pathway genes and a pro-angiogenic phenotype in CLL cells., Leuk Res, 32, 1565, 10.1016/j.leukres.2008.03.003 · DOI
- H Ning, 2008, The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study., Leukemia, 22, 593, 10.1038/sj.leu.2405090 · DOI · Paper page
- S Iwamoto, 2007, Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase., J Clin Invest, 117, 1049, 10.1172/JCI30235 · DOI · Paper page
- I Guest, 2009, Direct and indirect contribution of bone marrow derived cells to cancer., Int J Cancer
- H Hamada, 2005, Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy., Cancer Sci, 96, 149, 10.1111/j.1349-7006.2005.00032.x · DOI · Paper page
- M Studeny, 2004, Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents., J Natl Cancer Inst, 96, 1593, 10.1093/jnci/djh299 · DOI · Paper page
- P Au, 2008, Bone marrow derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature., Blood, 111, 4551, 10.1182/blood-2007-10-118273 · DOI · Paper page
- T Sato, 2004, Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases., Gynecol Oncol, 92, 47, 10.1016/j.ygyno.2003.09.012 · DOI
- P Amé-Thomas, 2007, Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis., Blood, 109, 693, 10.1182/blood-2006-05-020800 · DOI · Paper page
- T Lwin, 2007, Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kB (RelB/p52) in non-Hodgkin's lymphoma cells., Leukemia, 21, 1521, 10.1038/sj.leu.2404723 · DOI
- C Dierks, 2007, Essential role of stromally induced hedgehog signaling in B-cell malignancies., Nature Med, 13, 944, 10.1038/nm1614 · DOI · Paper page
- J Ruan, 2006, Magnitude of stromal hemangiogenesis correlates with histologic subtype of Non-Hodgkin's lymphoma., Clin Cancer Res, 12, 5622, 10.1158/1078-0432.CCR-06-1204 · DOI · Paper page
- DA Chan, 2009, Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment., Cancer Cell, 15, 527, 10.1016/j.ccr.2009.04.010 · DOI · Paper page
- YB Choi, 2010, Induction of angiogenic chemokine CCL2 by human herpesvirus 8., Virology, 397, 369, 10.1016/j.virol.2009.11.024 · DOI
- R Trouillon, 2010, Angiogenin induces nitric oxide synthesis in endothelial cells through PI-3 and Akt kinases., Biochemistry, 49, 3282, 10.1021/bi902122w · DOI
- A De Becker, 2007, Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3., Haematologica, 92, 440, 10.3324/haematol.10475 · DOI · Paper page
- Y Zhu, 2009, Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1., Leukemia, 23, 925, 10.1038/leu.2008.384 · DOI · Paper page
- K Otsu, 2009, Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells., Blood, 113, 4197, 10.1182/blood-2008-09-176198 · DOI · Paper page
- G Lazennec, 2008, Concise Review: Adult multipotent stromal cells and cancer: risk or benefit?, Stem Cells, 26, 1387, 10.1634/stemcells.2007-1006 · DOI · Paper page
- FC Marini, 2009, The complex love-hate relationship between mesenchymal stromal cells and tumors., Cytotherapy, 11, 375, 10.1080/14653240903098195 · doi:10.1080/14653240903098195
- P Secchiero, 2005, TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release., Blood, 105, 3413, 10.1182/blood-2004-10-4111 · DOI · Paper page
- P Secchiero, 2007, Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells., Curr Drug Metab, 8, 395, 10.2174/138920007780655432 · DOI
- P Secchiero, 2004, TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells., Cell Mol Life Sci, 61, 1965, 10.1007/s00018-004-4197-6 · DOI
Cited by
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562
Mesenchymal stem/stromal cells in cancer therapy
Lan, T., Luo, M., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01208-w · Cited by 374
Pakravan, K., Babashah, S., Sadeghizadeh, M., Mowla, S. J., Mossahebi-Mohammadi, M., Ataei, F., Dana, N., & Javan, M. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0335-7 · Cited by 346
Microvesicles Derived from Human Bone Marrow Mesenchymal Stem Cells Inhibit Tumor Growth
Bruno, S., Collino, F., Deregibus, M. C., Grange, C., Tetta, C., & Camussi, G. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0304 · Cited by 309
The roles of mesenchymal stem cells in tumor inflammatory microenvironment
Sun, Z., Wang, S., & Zhao, R. C. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-14 · Cited by 249
“N-MSCs can inhibit angiogenesis by inducing apoptosis in vascular endothelial cells [61,62] or by directly inhibiting vascular network formation [63].”
Background
Metadata
- Authors
- Secchiero, P., Zorzet, S., Tripodo, C., Corallini, F., Melloni, E., Caruso, L., Bosco, R., Ingrao, S., Zavan, B., & Zauli, G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-06-16
- Volume
- 5
- Issue
- 6
- Pages
- e11140
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2062465944
- Cited by
- 148
- References
- 11
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. https://app.cochat.ai/papers/10.1371/journal.pone.0011140
- The paper
- Secchiero, P., Zorzet, S., Tripodo, C., Corallini, F., Melloni, E., Caruso, L., Bosco, R., Ingrao, S., Zavan, B., & Zauli, G. (2010). Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. PLoS ONE. https://doi.org/10.1371/journal.pone.0011140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.